Shijiazhuang Yiling Pharmaceutical News

Eling Pharmaceutical (002603) 2023 Third Quarter Report Review: Short-term performance under pressure, R&D has been fruitful

華創證券Nov 2, 2023 07:42

Yiling Pharmaceutical (002603): Short-term performance under pressure, R&D pipeline enters the implementation period

德邦證券Nov 2, 2023 00:00

Yiling Pharmaceutical (002603): Short-term performance under pressure, patent Chinese medicine research and development continues to advance

華西證券Oct 31, 2023 00:00

Yiling Pharmaceutical (002603): Short-term R&D work in the respiratory sector continues to advance under pressure

平安證券Oct 30, 2023 15:32

Eling Pharmaceutical (002603): Short-term performance under pressure, insisting on innovative drug research and development to tap endogenous growth potential

民生證券Oct 30, 2023 00:00

Eling Pharmaceutical (002603) 2023 Third Quarter Report Review Report: Steady growth in the first three quarters is optimistic about the company's long-term development

國海證券Oct 29, 2023 00:00

Eling Pharmaceutical (002603): Lianhua drags down the steady state of mind, and academics are welcoming results again

華泰證券Oct 29, 2023 00:00

Eling Pharmaceutical (002603): COVID-19 performance continues to be digested, and innovative products are expected to continue to grow

國聯證券Oct 29, 2023 00:00

Yiling Pharmaceutical (002603): Short-term performance under pressure, continuous implementation of innovative achievements

安信證券Oct 28, 2023 00:00

Research Report Nuggets 丨 Haitong Securities: In the future, Eling Pharmaceutical will launch a number of innovative traditional Chinese medicine drugs one after another, maintaining a “superior to the market” rating

Gelonghui FinanceSep 21, 2023 17:05

Eling Pharmaceutical (002603): Non-respiratory products resume growth and development of patented traditional Chinese medicine continues to advance

海通證券Sep 21, 2023 10:26

Eling Pharmaceutical (002603): Non-respiratory products resume growth and development of patented traditional Chinese medicine continues to advance

海通國際Sep 21, 2023 00:00

Eling Pharmaceutical (002603): Cardiovascular and cerebrovascular stability second-line varieties are expected to be gradually released

東北證券Sep 4, 2023 00:00

Eling Pharmaceutical (002603): Maintains the lead in core areas and continues to grow at a high profit side

華安證券Aug 31, 2023 00:00

Eling Pharmaceutical (002603): Performance in the first half of the year is in line with expectations, innovation drives long-term high-quality development

中信建投證券Aug 30, 2023 15:36

Eling Pharmaceutical (002603): Performance is in line with expectations, cardiovascular and other products are recovering steadily

華西證券Aug 30, 2023 00:00

Eling Pharmaceutical (002603): Stable performance growth and sufficient reserves

國海證券Aug 29, 2023 00:00

Eling Pharmaceutical (002603) 2023 semi-annual report review: Performance growth is in line with expectations, traditional Chinese medicine research and development is progressing smoothly

西部證券Aug 28, 2023 00:00

Eling Pharmaceutical (002603): Traditional Chinese Medicine Innovation Leaders Drive Development with Multiple Varieties

東北證券Aug 15, 2023 00:00

Eling Pharmaceutical (002603) 2023 semi-annual performance forecast review: Performance growth is basically in line with expectations, and research and development of Chinese medicine varieties is progressing smoothly

西部證券Jul 16, 2023 00:00